ST. LOUIS, June 29, 2026 (GLOBE NEWSWIRE) — The Marketing Alliance, Inc. (OTC: MAAL) (“TMA” or the “Company”), announced its financial results today for its fiscal 2026 year ended March 31, 2026. FY2026 Financial Key Items (all comparisons to the prior year)Operating income from continuing operations of $1,010,017 compared to $730,005 in the prior year, an increase of over 38%   Net income was $656,420 or $0.10 per share compared to $465,599 or $0.06 per share in the prior year Revenues from operations were $18,933,531 compared to $21,373,673 in the prior fiscal year Subsequent to the end of the quarter, on May 15, 2026, the Company announced it had sold to an unaffiliated purchaser substantially all of the equipment assets of its construction business, Empire Construction, Inc., and all of the real property associated with the...

Roadzen Posts First ‘Rule of 40’ Quarter in Two Years; FY2026 Net Loss Narrows 69% and Adjusted EBITDA Loss Improves 58%, with Seventh Straight Quarter of Adjusted EBITDA Gains Nearing BreakevenRecord Revenue Growth Drives Strongest Quarter in Company HistoryRoadzen delivered record fourth-quarter revenue of $16.1 million, up 42% year-over-year and 12% sequentially — the highest quarterly revenue in Company history. Full-year FY2026 revenue rose to a record $55.0 million, up 24% from $44.3 million in FY2025, reflecting sustained multi-quarter acceleration driven by rising customer adoption and expanding enterprise penetration. Net Loss Narrows Sharply; Adjusted EBITDA1 Approaches Break-EvenNet loss attributable to ordinary shareholders for FY2026 fell approximately 69% to $(22.5) million, or $(0.29) per share, from $(72.9) million, or...

WOBURN, Mass., June 29, 2026 (GLOBE NEWSWIRE) — Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and year ended March 31, 2026 and provided a business update. The Company recently announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. The FDA considers this a complete, class 1 response with a goal date of August 2, 2026, and has notified the company to expect an advisory committee meeting in late July. “The FDA’s acceptance of our RP1 BLA resubmission marks a pivotal milestone in our mission...

– Recently closed $50 million underwritten offering reinforces strong institutional investor conviction and bolsters balance sheet for execution of second Phase 3 HLP003 trial1,2,3, EMBRACE, for potential U.S. FDA New Drug Application in 20281,2,3 – – Phase 3 APPROACH pivotal study of HLP003 in Major Depressive Disorder (“MDD”) has surpassed 88% enrollment and is on track for topline data readout in Q4 20262,3 – – HLP003 Phase 2 data demonstrated durability at 12 months following two 16mg doses, with 100% response and 71% remission based on a MADRS benchmark of ≤10, with remission rising to 100% based on recent peer benchmarks of ≤124,5 – – Reported topline results in Phase 2 signal detection study for HLP004 in Generalized Anxiety Disorder (“GAD”) showing ~10-point improvement from baseline in...

LIKMEZ® (ATI-1501) commercial momentum building in U.S. market US$40 million NIAID award supporting VXV-01 advancement through Phase 1 HALIFAX, Nova Scotia, June 26, 2026 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the fiscal year ended March 31, 2026 (“FYE 2026”), and provided an update on fiscal 2027. All figures are stated in Canadian dollars unless otherwise stated. “Fiscal year 2026 marked a significant transition for Appili as we advanced commercial-stage programs and continued to build our non-dilutive funding base,” said Don Cilla, Pharm.D., M.B.A., President and CEO of Appili Therapeutics. “With...

First Half Fiscal Year 2026 Revenue up 7.7% to $17.7 Million Period over Period Accelerating Enterprise AI Adoption Fuels Market Expansion, Unlocking New Opportunities in AI-Powered Customer Engagement SAN DIEGO and SINGAPORE, June 26, 2026 (GLOBE NEWSWIRE) — Helport AI Limited (NASDAQ: HPAI) (“Helport AI” or the “Company”), a global artificial intelligence (“AI”) workforce infrastructure company providing intelligent communication software and services to enterprise clients, today announced its unaudited financial results for the six months ended December 31, 2025. First Half Fiscal Year 2026 Highlights  Average monthly subscribed users of AI Assist services were 37,908 for the six months ended December 31, 2025, representing an increase of 16.8% from 32,468 in the same period of 2024.Revenue for the six months ended December...

MERIDIAN, Idaho, June 26, 2026 (GLOBE NEWSWIRE) — PCS Edventures!, Inc. (“PCSV”), a leading provider of TK-12 Science, Technology, Engineering and Mathematics (“STEM”) education programs, today announced results of operations for its fiscal year ended March 31, 2026. Full Year 2026 Overview:Revenue decreased 14.4% to $6.3 million compared to the prior year. Gross margin of 60.5% in FY 2026. Net income before income tax provision decreased 74.6% to $321,455 versus last year. Cash on hand at the end of FY 2026 was $2.7 million. The Company has no debt. Shares outstanding decreased 4.66% to 9,707,960 shares, as 481,561 shares were repurchased during FY 2026.Mike Bledsoe, President, commented, “Our market during fiscal year 2026 was again challenging due to uncertainties about funding amounts and funding processes. This uncertainty...

MDNA11, as a single agent or in combination with pembrolizumab, continues to demonstrate compelling anti-tumor activity in patients with advanced or metastatic cutaneous melanoma, endometrial cancer and gastrointestinal cancers unresponsive to checkpoint inhibitors Enrolment in ABILITY-1 to be completed in Q3 2026 with key data readouts expected in Q4 2026 which will guide development strategy for a potential registrational pathway and partnerships Enrolment in the NEO-CYT Phase 1b trial, funded by Fondazion Melanoma, is well underway. In this study, which was highlighted at ASCO 2026, MDNA11 is being evaluated in combination with checkpoint inhibitors for the treatment of advanced melanoma prior to surgery Data presented at AACR 2026 showed that MDNA113, Medicenna’s anti-PD1-IL-2 bifunctional immunotherapy, was safer even at doses 30-fold...

Subscription revenues increased 36% from the comparative year-ago period to $3.0 million Operating expenses decreased 13% from the comparative year-ago period Net Loss improved by $1.3 million, or 36% from the comparative year-ago periodPERTH, Australia, June 26, 2026 (GLOBE NEWSWIRE) — Locafy Limited (Nasdaq: LCFY, LCFYW) (“Locafy” or the “Company”), a globally recognized software-as-a-service (SaaS) technology company specializing in location-based Search Engine Optimization (SEO) and Answer Engine Optimization (AEO) solutions, today reported financial results for the fiscal nine-month period ended March 31, 2026, with solid year-over-year improvements in all key metrics. All financial results are reported in Australian dollars (AUD). Business HighlightsSubscription revenues increased by 36% on the back of core SEO/AEO product...

Revenue increased by 107% year-over-year to $7.7 million in the full fiscal year 2026; increased revenue by 66% YoY in the fiscal fourth quarter 2026 The Company is transitioning its year-end from March 31st to December 31st Announced revenue guidance of $8 million for the year ending December 31, 2026 which represents approximately 15% growth; and $16-$18 million or more than 110% growth for the year ending December 31, 2027 Conference call at 8:00 a.m. ET today, June 26th GARDEN CITY, N.Y., June 26, 2026 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients’ lives, today announced its financial results for the fiscal fourth quarter and year ended March 31,...